ArticleAnnals of surgical oncology2025
Exploring the Impact of 5-Alpha Reductase Inhibitors on Bladder Cancer: Insights from a Large-Scale Prospective Cohort Study.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Single-cell analysis reveal cell-type-specific RNA methylation patterns in breast cancer.The Journal of international medical research · 2025Article
- Trends in global and national infertility and factors associated with primary infertile couples in recent middle-aged Chinese.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEmerging studies on the effect of 5-alpha reductase inhibitors (5ARIs) on bladder cancer (BC) risk yielded conflicting results. We aimed to explore the anti-tumor effect of 5ARIs on BC incidence, BC recurrence, BC risk of undergoing radical cystectomy, and BC-related mortality.
methodsIn this prospective cohort of 227,847 individuals from the UK biobank, we constructed the follow-up cohorts on 1 January 2011, with only the male population being included. The cohorts were followed up until 27 November 2023, when we conducted this study. Information on the medication of 5ARIs was recorded. The primary endpoints were the rate of BC incidence and BC-related mortality, while the secondary endpoints were the rate of BC local recurrence and BC risk of undergoing radical cystectomy. A strict and comprehensive sensitivity analysis was performed.
resultsA total of 227,847 individuals without BC diagnosis at baseline were included for analysis. During a median follow-up of 12.9 years, there were 2487 new-onset BC events. 5ARI medication did not lower the risk of BC incidence significantly (hazard ratio 0.72, 95% confidence interval [CI] 0.43-1.18). When cumulative 5ARI medication duration exceeded 3 years, 5ARI medication only had a slight influence on BC incidence (life expectancy difference [LED] 12.04 days, 95% CI 2.54-21.54 for 3 years; LED 10.00 days, 95% CI 3.61-16.39 for 5 years). However, 5ARI medication predicted a higher risk of BC-related mortality (LED -867.84 days, 95% CI -1637.15 to -98.52) and BC risk of undergoing radical cystectomy (LED -955.83 days, 95% CI -1796.89 to -114.76) during a more than 10-year follow-up duration.
conclusionsWe did not find a strong protective role of 5ARIs in reducing the risk of BC incidence, BC-related mortality, BC local recurrence, and BC risk of undergoing radical cystectomy. A randomized controlled trial is warranted in the future.
Indexed as
Identifiers
40754544What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.